Symptomatic Intracranial Hemorrhage following Intravenous Thrombolysis for Acute Ischemic Stroke: A Critical Review of Case Definitions

被引:169
作者
Seet, Raymond C. S. [1 ,2 ]
Rabinstein, Alejandro A. [1 ]
机构
[1] Mayo Clin, Dept Neurol, Rochester, MN USA
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
Recombinant tissue plasminogen activator; Ischemic stroke; Symptomatic intracranial hemorrhage; TISSUE-PLASMINOGEN-ACTIVATOR; INTRACEREBRAL HEMORRHAGE; CANADIAN ALTEPLASE; CLINICAL-PRACTICE; H; THERAPY; EXPERIENCE; SAFETY; RISK; CLASSIFICATION;
D O I
10.1159/000339675
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Symptomatic intracranial hemorrhage (SICH) is a devastating complication of intravenous thrombolysis treatment that is associated with high mortality. Clinical trials, stroke registries and cohort studies employ different case definitions to identify stroke patients with SICH following intravenous thrombolysis. We systematically reviewed the reported rates of SICH following intravenous thrombolysis and compared their consistency with mortality outcomes. Methods: Studies were identified from the PubMed and Embase databases from January 1994 to July 2011 by cross-referencing the following MeSH terms: 'thrombolysis', 'recombinant tissue plasminogen activator', 'rtPA', 'hemorrhagic stroke', 'cerebral hemorrhage', 'hematoma' and 'ischemic stroke'. Demographic information, baseline National Institute of Health Stroke Scale (NIHSS) scores, time from stroke onset to intravenous thrombolysis, SICH and mortality rates were derived from published data in 7 randomized controlled trials, 7 stroke registries and 10 cohort studies (4 multicenter and 6 single center) with more than 200 consecutively recruited patients. Mortality rates were considered as the percentage of patients treated with intravenous thrombolysis who died within 90 days after stroke. Results: The mean age of patients included in this analysis was 68.8 years (standard deviation, SD 2.9, range 63-75), of whom 56.3% (SD 4.5, range 45-63) were men. They presented with a mean baseline NIHSS of 12.5 (SD 1.4, range 9-15) and received intravenous thrombolysis 175 min (SD 62, range 120-328) from stroke onset. The overall mean SICH and mortality rates of patients treated with intravenous thrombolysis were 5.6% (SD 2.3) and 14.7% (SD 4.8), respectively. A moderate correlation was observed between the incidence of SICH and mortality in patients treated with intravenous thrombolysis (r = 0.401, p = 0.050). The variation in SICH rates was highest across studies that reported SICH rates using the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria compared with the European Cooperative Acute Stroke Study and National Institute of Neurological Disorders and Stroke (NINDS) criteria. Studies that defined SICH as parenchymal hemorrhage with a neurological decline NIHSS >= 4 occurring within 36 h of intravenous thrombolysis reported a higher consistency between SICH and mortality rates (correlation coefficient 0.631). Conclusions: SICH rates vary considerably between studies and these differences may relate to the differences in the criteria used to define SICH. Until a case definition with high inter-rater agreement and good correlation with stroke outcomes becomes available, detailed information on the type of bleeding, the extent of NIHSS deterioration, neuroimaging features and the time from thrombolysis to diagnosis of hemorrhage should be reported to permit a correct interpretation of SICH rates. Copyright (c) 2012 S. Karger AG, Basel
引用
收藏
页码:106 / 114
页数:9
相关论文
共 35 条
  • [11] Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke Patient Characteristics, Hospital Factors, and Outcomes Associated With Door-to-Needle Times Within 60 Minutes
    Fonarow, Gregg C.
    Smith, Eric E.
    Saver, Jeffrey L.
    Reeves, Mathew J.
    Bhatt, Deepak L.
    Grau-Sepulveda, Maria V.
    Olson, DaiWai M.
    Hernandez, Adrian F.
    Peterson, Eric D.
    Schwamm, Lee H.
    [J]. CIRCULATION, 2011, 123 (07) : 750 - U184
  • [12] Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial
    Furlan, A
    Higashida, R
    Wechsler, L
    Gent, M
    Rowley, H
    Kase, C
    Pessin, M
    Ahuja, A
    Callahan, F
    Clark, WM
    Silver, F
    Rivera, F
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 2003 - 2011
  • [13] Tissue plasminogen activator for acute ischemic stroke in clinical practice - A meta-analysis of safety data
    Graham, GD
    [J]. STROKE, 2003, 34 (12) : 2847 - 2850
  • [14] Intravenous tissue-type plasminogen activator therapy for ischemic stroke - Houston experience 1996 to 2000
    Grotta, JC
    Burgin, WS
    El-Mitwalli, A
    Long, M
    Campbell, M
    Morgenstern, LB
    Malkoff, M
    Alexandrov, AV
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (12) : 2009 - 2013
  • [15] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
    Hacke, W
    Kaste, M
    Fieschi, C
    von Kummer, R
    Davalos, A
    Meier, D
    Larrue, V
    Bluhmki, E
    Davis, S
    Donnan, G
    Schneider, D
    Diez-Tejedor, E
    Trouillas, P
    [J]. LANCET, 1998, 352 (9136) : 1245 - 1251
  • [16] HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
  • [17] Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke
    Hacke, Werner
    Kaste, Markku
    Bluhmki, Erich
    Brozman, Miroslav
    Davalos, Antoni
    Guidetti, Donata
    Larrue, Vincent
    Lees, Kennedy R.
    Medeghri, Zakaria
    Machnig, Thomas
    Schneider, Dietmar
    von Kummer, Ruediger
    Wahlgren, Nils
    Toni, Danilo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (13) : 1317 - 1329
  • [18] URGENT THERAPY FOR STROKE .2. PILOT-STUDY OF TISSUE PLASMINOGEN-ACTIVATOR ADMINISTERED 91-180 MINUTES FROM ONSET
    HALEY, EC
    LEVY, DE
    BROTT, TG
    SHEPPARD, GL
    WONG, MCW
    KONGABLE, GL
    TORNER, JC
    MARLER, JR
    [J]. STROKE, 1992, 23 (05) : 641 - 645
  • [19] Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study
    Hill, MD
    Buchan, AM
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (10) : 1307 - 1312
  • [20] MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset:: a cohort study
    Koehrmann, Martin
    Juettler, Eric
    Fiebach, Jochen B.
    Huttner, Hagen B.
    Siebert, Stefan
    Schwark, Christian
    Ringleb, Peter A.
    Schellinger, Peter D.
    Hacke, Werner
    [J]. LANCET NEUROLOGY, 2006, 5 (08) : 661 - 667